<DOC>
	<DOCNO>NCT02109861</DOCNO>
	<brief_summary>The purpose study identify specific gene up- downregulated multiple myeloma patient receive microdose either Melphalan ( Alkeran® ) , Bortezomib ( Velcade® ) Dexamethasone ( Dexaven® ) . The study treatment constitute 1 % plan standard myeloma treatment give two hour prior standard treatment . Blood sample take baseline , 15 , 30 , 60 120 minute microarray analysis .</brief_summary>
	<brief_title>Microdose Study Melphalan , Bortezomib Dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Planned treatment Multiple Myeloma ( newly diagnose well relapse refractory disease ) one follow chemotherapy regimen : 1 ) Highdose melphalan , 2 ) Bortezomib 3 ) Dexamethasone 18 year old . Understand sign inform consent . Prior treatment study drug Received treatment biphosphonates week prior study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Phase 0 study</keyword>
	<keyword>Microdose study</keyword>
	<keyword>Micro array</keyword>
	<keyword>Gene expression profile</keyword>
</DOC>